Pharmacometrics – University of Copenhagen

Forward this page to a friend Resize Print Bookmark and Share

Department of Drug Design and Pharmacology > Research > Pharmacotherapy > Pharmacometrics

Pharmacometrics: Population pharmacokinetic/pharmacodynamic (PK-PD) modelling

Describing the plasma concentration-time profile (pharmacokinetics, PK) and understanding the quantitative link to therapeutic response (PK-PD) of a drug is paramount for selection of the optimal dosage amount and frequency to treat patients and minimise unwanted adverse events.

PK-PD modelling (also referred to as pharmacometrics or quantitative pharmacology) is the science of developing simplified computer-based models that provide useful mechanistic understanding of the processes involved in drug disposition and corresponding therapeutic effect as a function of time.

Non-linear mixed effects - or "population" PK-PD - modelling allows for analysis of both the population mean response in addition to description and explanation of inter-individual differences in therapeutic response and characterization of residual variability in studies.

Population PK-PD models can be used for simulation of study trial outcome with different dosage regiments. Furthermore, PK-PD models based on translational biomarkers is a useful tool to predict patient response based on experimental disease models. This makes PK-PD modelling a strong analytical tool that plays an increasing role in drug research & development in the pharmaceutical industry.

PK-PD modelling is applicable to a wide range of pharmacological areas and can be used to analyse data from both animal and human studies.


  • Analgesic response of opioids in healthy volunteers
  • Gastro-intestinal absorption mechanisms of anti-epileptics in rats
  • Translating PK-PD relationship of human growth hormone between humans and animal models
  • Lymphatic transport of therapeutic proteins in rats after subcutaneous administration
  • Steady-state pharmacokinetics and –dynamics of morphine after administration of controlled release and immediate release tablets
  • Translational post-operative pain models - modelling patient-controlled opioid consumption as marker of analgesic efficacy
  • Population PK-PD of morphine


We currently have international scientific collaborations with highly esteemed academic pharmacometrics research groups and clinical research units at:

  • Uppsala University (Sweden)
  • Australian Centre for Pharmacometrics at University of South Australia, Adelaide, and Monash University, Melbourne (Australia)
  • University of California, San Fransisco
  • Mech-Sense Center at Aalborg Hospital

Furthermore, we aim at close integration of our academic research with the pharmaceutical industry, where we have collaborations with:

  • Novo Nordisk A/S
  • H. Lundbeck